What Is Ecnoglutide? The Biased GLP-1 Agonist Now Approved in China and Being Developed as an Oral Tablet

Most GLP-1 medicines activate the same receptor.

But they do not necessarily activate that receptor in exactly the same way.

Ecnoglutide, also known as XW003, is a newer peptide-based GLP-1 receptor agonist designed around the concept of biased signalling.

Rather than strongly activating every signalling pathway connected to the GLP-1 receptor, ecnoglutide preferentially activates the cyclic AMP, or cAMP, pathway while producing less β-arrestin recruitment.

This makes it scientifically different from simply producing another longer-lasting version of GLP-1.

And ecnoglutide has now moved well beyond early experimental research.

In 2026, the injectable formulation became approved in China for both type 2 diabetes and chronic weight management, while an oral tablet formulation remains under clinical investigation. (Sciwind Biosciences⁠)

What Is Ecnoglutide?

Ecnoglutide is a long-acting GLP-1 receptor agonist peptide developed by Sciwind Biosciences.

It was originally known by the development code XW003.

The injectable formulation is designed for once-weekly administration.

Like other GLP-1 receptor agonists, it mimics aspects of the naturally occurring hormone GLP-1.

But its signalling profile is intentionally different.

What Does GLP-1 Normally Do?

GLP-1 stands for glucagon-like peptide-1.

It is a naturally occurring hormone released from the intestine after food is consumed.

Among its physiological roles, GLP-1 contributes to:

• insulin secretion
• glucose regulation
• appetite control
• satiety
• gastric emptying

These effects explain why GLP-1 receptor agonists have become important medicines for diabetes and obesity.

What Makes Ecnoglutide Different?

The key term is biased agonism.

When a molecule activates a receptor, that receptor can trigger several different signalling pathways inside the cell.

Two important pathways associated with the GLP-1 receptor involve:

• cAMP
• β-arrestin

Ecnoglutide has been engineered to favour cAMP signalling over β-arrestin recruitment.

That is why it is described as a cAMP-biased GLP-1 receptor agonist. (ScienceDirect⁠)

Why Might Biased Signalling Matter?

Receptors do not simply behave like basic on/off switches.

Different molecules can activate the same receptor but create different patterns of intracellular signalling.

Researchers are interested in whether greater cAMP signalling with reduced β-arrestin recruitment could potentially influence:

• receptor sensitivity
• duration of signalling
• insulin secretion
• appetite effects
• weight reduction
• tolerability

The important point is that biased signalling is a pharmacological strategy.

It does not automatically mean a drug will be superior to other GLP-1 receptor agonists.

Clinical trials still have to demonstrate whether the altered signalling translates into meaningful benefits.

What Did the Phase 3 Weight-Loss Trial Show?

A multicentre Phase 3 trial published in The Lancet Diabetes & Endocrinology investigated ecnoglutide in 664 adults with overweight or obesity without diabetes.

Participants received once-weekly ecnoglutide at doses of:

• 1.2 mg
• 1.8 mg
• 2.4 mg

or placebo.

At week 40, average body-weight changes were approximately:

• –9.1% with 1.2 mg
• –10.9% with 1.8 mg
• –13.2% with 2.4 mg
• +0.1% with placebo

Around 87% of participants receiving 2.4 mg achieved at least 5% weight reduction, compared with 16% receiving placebo. (PubMed⁠)

What Were the Side Effects?

The most commonly reported adverse effects were gastrointestinal.

These were generally described as mild to moderate.

Treatment-emergent adverse events occurred in around 93% of participants receiving ecnoglutide compared with 84% receiving placebo.

Ten participants receiving ecnoglutide discontinued treatment because of adverse events. (PubMed⁠)

This pattern is broadly consistent with the gastrointestinal tolerability issues already associated with the wider GLP-1 drug class.

Has Ecnoglutide Been Compared With Other GLP-1 Drugs?

Yes.

A separate Phase 3 trial compared ecnoglutide with dulaglutide in adults with type 2 diabetes whose glucose remained elevated while taking metformin.

The 52-week study specifically examined whether ecnoglutide could provide comparable or improved glucose control relative to dulaglutide.

The trial confirmed that ecnoglutide could produce substantial glycaemic improvements while providing additional evidence about the compound’s safety and metabolic effects. (ScienceDirect⁠)

What About Semaglutide?

Sciwind reported head-to-head clinical data in 2026 comparing ecnoglutide with semaglutide and stated that ecnoglutide produced greater weight reduction in the studied population.

However, company-reported head-to-head findings should be interpreted in the context of the exact doses, patient population and study design before concluding that one drug is universally superior. (Sciwind Biosciences⁠)

Direct comparisons are particularly valuable because the obesity field now contains effective established treatments.

The question is increasingly not simply whether a new GLP-1 works, but how it compares with current alternatives.

Is Ecnoglutide Still Experimental?

That depends on where you are.

Ecnoglutide injection is no longer purely experimental in China.

China’s National Medical Products Administration approved the injectable formulation for adults with type 2 diabetes in January 2026. (Sciwind Biosciences⁠)

It was then approved for chronic weight management in Chinese adults with overweight or obesity in March 2026. (PR Newswire⁠)

However, that does not mean ecnoglutide is approved globally.

Approval in one country does not automatically extend to the UK, US, EU or other markets.

Why Is the China Approval Important?

It makes ecnoglutide particularly interesting from a research perspective.

Many peptides discussed online remain:

• preclinical
• Phase 1
• Phase 2
• or early Phase 3 candidates

Ecnoglutide has already crossed the regulatory threshold in a major pharmaceutical market.

That means its development has progressed from experimental pharmacology into real clinical use in China.

Is There an Oral Version?

Yes.

This may become one of the most interesting developments in the ecnoglutide programme.

An oral formulation, also called VRB-101 in development outside China, is being investigated for obesity and weight management.

A Phase 1b/2a study in China is evaluating oral ecnoglutide tablets in people with overweight or obesity.

Some study groups receive the tablets daily for short periods, while others receive once-weekly oral dosing for up to 24 weeks. (ICHGCP⁠)

Once-Weekly Oral GLP-1?

Potentially.

This is what makes oral ecnoglutide particularly unusual.

Many oral medicines are taken once daily.

The ongoing study includes cohorts receiving ecnoglutide tablets once weekly.

If researchers can demonstrate adequate absorption and sustained activity from a weekly tablet, this could offer a significantly different treatment model.

However, the oral programme remains investigational.

Why Are Peptides Difficult to Give Orally?

Peptides are vulnerable to digestion.

The gastrointestinal system is specifically designed to break proteins and peptides into smaller components.

This creates two major problems:

1. the peptide can be degraded before reaching the bloodstream;
2. large peptide molecules generally cross the intestinal wall poorly.

Oral peptide formulations therefore require specialised pharmaceutical technology to achieve useful absorption.

Is Oral Ecnoglutide Being Studied for Weight Maintenance?

Yes.

A Phase 2 study involving VRB-101 has investigated weekly oral ecnoglutide specifically as a weight-maintenance therapy.

Participants entered the trial after previously losing weight through approximately six months of injectable semaglutide or tirzepatide treatment.

Researchers are testing whether weekly oral ecnoglutide can help maintain that weight reduction. (ICHGCP⁠)

This is a particularly interesting research direction.

Why Is Weight Maintenance Becoming Important?

Modern obesity medicines can produce substantial weight reduction.

The increasingly important question is what happens afterward.

When effective metabolic treatment stops, weight regain can occur.

Researchers are therefore beginning to explore treatment strategies involving:

an intensive initial weight-loss phase

followed by

a simpler or less frequent maintenance phase.

A weekly oral peptide could potentially fit into this model if future trials demonstrate that it works.

Is Oral Ecnoglutide Being Combined With Other Drugs?

Yes.

Another clinical programme is investigating oral ecnoglutide, VRB-101, alongside an experimental compound called VRB-103.

The Phase 1 study includes more than 300 planned participants and is evaluating the safety and tolerability of VRB-103 alone and in combination with oral ecnoglutide. (trialticker⁠)

This reflects another major direction in metabolic research: combining multiple mechanisms while trying to keep treatment entirely oral.

Is Ecnoglutide Being Studied Beyond Standard Adult Obesity?

Yes.

The clinical programme has expanded into several additional populations.

Current studies include research involving:

• adolescents with obesity
• people with obesity and obstructive sleep apnoea
• people with obesity and knee osteoarthritis
• switching from other GLP-1 therapies
• weight maintenance

This is typical of a metabolic drug that has moved beyond initial proof of efficacy into broader investigation.

How Is Ecnoglutide Different From Tirzepatide?

Their receptor profiles are fundamentally different.

Ecnoglutide targets:

GLP-1

Tirzepatide targets:

GIP + GLP-1

Tirzepatide therefore uses dual receptor agonism.

Ecnoglutide instead attempts to optimise what happens inside the cell after the GLP-1 receptor itself is activated.

That makes the strategies conceptually different.

How Is Ecnoglutide Different From Survodutide?

Survodutide activates:

GLP-1 + glucagon

Ecnoglutide primarily targets:

GLP-1

Again, ecnoglutide’s distinguishing feature is not additional receptor targets but biased GLP-1 receptor signalling.

How Is Ecnoglutide Different From VK2735 or Ribupatide?

Both VK2735 and ribupatide activate:

GIP + GLP-1

Ecnoglutide does not attempt to add GIP signalling.

Instead, its developers have focused on changing the way the GLP-1 receptor itself signals.

This means the current metabolic pipeline is effectively testing two competing ideas:

Can more receptors produce better results?

versus

Can signalling through one receptor be optimised more precisely?

Both strategies may ultimately prove useful.

Is Ecnoglutide a Peptide?

Yes.

Ecnoglutide is a peptide-based GLP-1 receptor agonist.

This distinguishes it from emerging oral small-molecule GLP-1 agonists such as orforglipron and elecoglipron.

Its oral formulation is therefore particularly noteworthy because oral delivery of peptide drugs is technically much more difficult than oral delivery of conventional small molecules.

Why Is Ecnoglutide Important?

Ecnoglutide is interesting for three separate reasons.

First, it represents one of the clearest clinical tests of biased GLP-1 receptor agonism.

Second, the injectable formulation has already achieved regulatory approval in China.

Third, researchers are now attempting to translate the same molecule into an oral formulation, potentially including once-weekly tablet dosing.

Together, those developments make ecnoglutide more than simply another experimental GLP-1.

What Still Needs to Be Answered?

Important questions remain, particularly outside China.

Researchers still need to determine:

• how ecnoglutide performs across more diverse populations
• whether biased signalling produces clinically meaningful advantages
• long-term cardiovascular outcomes
• comparative performance against established GLP-1 and dual agonists
• whether the oral formulation can reproduce injectable effectiveness
• how reliable weekly oral absorption will be
• whether oral treatment can successfully maintain prior weight reduction
• long-term safety

The injectable drug has substantially more evidence behind it than the oral formulation.

Those two stages of development should not be confused.

The Bottom Line

Ecnoglutide, also known as XW003, is a peptide-based cAMP-biased GLP-1 receptor agonist.

In a published Phase 3 obesity trial involving 664 participants, the highest studied dose produced average weight reduction of approximately 13.2% at 40 weeks, compared with virtually no average change in the placebo group. (PubMed⁠)

Unlike most emerging peptides we have covered, injectable ecnoglutide has already reached the market in one country.

China approved it for type 2 diabetes in January 2026 and chronic weight management in March 2026. (Sciwind Biosciences⁠)

The next major question is whether ecnoglutide can successfully make the transition from injection to tablet.

Clinical studies are now investigating oral ecnoglutide, including the unusual possibility of once-weekly oral dosing and its use for maintaining weight after injectable GLP-1-based treatment. (ICHGCP⁠)

That combination of biased signalling, established Phase 3 evidence, Chinese regulatory approval and an emerging oral programme makes ecnoglutide one of the more scientifically interesting GLP-1 peptides to follow.

This article is for research and educational purposes only. Regulatory approval differs by country, and discussion of investigational oral ecnoglutide does not establish it as safe, effective or approved for human use.